DOTMV·shop.mvrent.mvEN
Explore
MedicinePOM

Olaparib

Olaparib is a targeted PARP-inhibitor tablet for certain ovarian, breast, pancreatic and prostate cancers.

Clinical information

Common uses

  • BRCA-mutated ovarian cancer (maintenance)
  • BRCA-mutated breast cancer
  • BRCA-mutated pancreatic cancer (maintenance)
  • certain advanced prostate cancers

Common side effects

  • feeling sick
  • tiredness
  • anaemia
  • vomiting
  • diarrhoea

Cautions

  • rare bone marrow cancers (MDS/AML) — monthly blood monitoring
  • lung inflammation (pneumonitis) can occur
  • risk of blood clots, including pulmonary embolism
  • can harm an unborn baby — use effective contraception

Interactions

  • strong or moderate CYP3A inhibitors — avoid or reduce dose
  • strong or moderate CYP3A inducers — avoid

Pregnancy: can harm an unborn baby — avoid

Reference information, not medical advice — always follow your doctor or pharmacist. Source: DailyMed, dailymed.nlm.nih.gov, olaparib (Lynparza) label, setid 741ff3e3-dc1a-45a6-84e5-2481b27131aa (accessed 2026-08-16)

Approved brands & formulations6

Brand nameDosage formStrengthImporterCategory
LynparzaTablet ( Film coated )150mgState Trading Organization PlcPOM
Lynparza 100mgTablet ( Film coated )100mgState Trading Organization PlcPOM
OlaparibTablet150mg—POM
OlaparibCapsule100mg—POM
OlaparibCapsule200mg—POM
OlaparibCapsule50mg—POM
Old search API